Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk
Clinical Journal of the American Society of Nephrology · 2025-02 · 20 (2) · 206-217
DOI: 10.2215/cjn.0000000587 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 08.10.2024. Verfasst von Joshua J Neumiller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy, Washington State University, Spokane, Washington. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Patient-Centered Outcomes Research Institute, University of Maryland Institute for Health Computing, Montgomery County Government, University of Maryland, Balt…, Patient-Centered Outcomes Research Institute.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Key Points Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists were superior to dipeptidyl peptidase-4 inhibitor and sulfonylurea for preventing kidney complications in patients with type 2 diabetes at moderate cardiovascular disease risk. Sodium-glucose cotransporter 2 inhibitor therapy compared favorably with glucagon-like peptide-1 receptor agonists for kidney disease outcomes.
Background
CKD is a serious diabetes-related complication. While guidelines recommend use of sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapies to mitigate cardiorenal risk in high-risk patients, the benefit of early initiation of these agents relative to other commonly prescribed glucose-lowering agents in patients at lower baseline cardiovascular disease (CVD) risk remains less clear.
Methods
This retrospective observational study emulated an idealized target trial using claims data from OptumLabs data warehouse to test the comparative association of treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4i), SGLT2i, GLP-1RA, or sulfonylurea (SU) on a primary kidney composite outcome of incident CKD stages 3–5, kidney failure, or need for KRT in patients with type 2 diabetes and moderate CVD risk. A secondary composite outcome included all components of the primary composite outcome plus death.
Results
A total of 364,714 adults aged 21 years or older initiating treatment with a DPP-4i ( N =78,843), GLP-1RA ( N =42,049), SGLT2i ( N =45,466), or SU ( N =198,356) were identified. Relative to DPP-4i, SGLT2i (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.67 to 0.74; P < 0.001) and GLP-1RA (HR, 0.87; 95% CI, 0.83 to 0.92; P < 0.001) treatment was superior for the primary composite outcome. Similarly, SGLT2i (HR, 0.69; 95% CI, 0.66 to 0.73) and GLP-1RA (HR, 0.86; 95% CI, 0.82 to 0.91) treatment was associated with risk reductions for the primary outcome relative to SU treatment. When comparing SGLT2i with GLP-1RA therapy, SGLT2is were superior for the primary composite outcome (HR, 0.81; 95% CI, 0.75 to 0.86; P < 0.001). Similar findings were observed for the secondary composite outcome across all comparisons.
Conclusions
SGLT2is and GLP-1RAs were superior to DPP-4is and SUs for preventing kidney complications in a type 2 diabetes population with moderate baseline CVD risk. Clinical Trial registry name and registration number: NCT05214573.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy, Washington State University, Spokane, Washington.
- Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut.
- Division of Health Care Delivery Research, Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota.
- OptumLabs, Eden Prairie, Minnesota.
- Department of Public Health Sciences, University of Chicago, Chicago, Illinois.
- Division of Endocrinology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.
ORCID-Profile: Joshua J Neumiller, Jeph Herrin, Rodolfo J Galindo, Joseph S Ross, Rozalina G McCoy
Förderung
- NCATS NIH HHS
- Patient-Centered Outcomes Research Institute, University of Maryland Institute for Health Computing, Montgomery County Government, University of Maryland, Balt…
- Patient-Centered Outcomes Research Institute
- University of Maryland Institute for Health Computing
- Montgomery County Government
- University of Maryland, Baltimore
- University of Maryland, College Park
Zitieren
APA
Neumiller, J. J., Herrin, J., Swarna, K. S., Polley, E. C., Galindo, R. J., Umpierrez, G. E., Deng, Y., Ross, J. S., Mickelson, M. M., & McCoy, R. G. (2025). Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk. Clinical Journal of the American Society of Nephrology, 20(2), 206-217. https://doi.org/10.2215/cjn.0000000587
Vancouver
Neumiller JJ, Herrin J, Swarna KS, Polley EC, Galindo RJ, Umpierrez GE, et al. Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk. Clinical Journal of the American Society of Nephrology. 2025;20(2):206-217. doi:10.2215/cjn.0000000587
BibTeX
@article{Neumiller2025,
author = {Neumiller, Joshua J and Herrin, Jeph and Swarna, Kavya Sindhu and Polley, Eric C and Galindo, Rodolfo J and Umpierrez, Guillermo E and Deng, Yihong and Ross, Joseph S and Mickelson, Mindy M and McCoy, Rozalina G},
title = {Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2025},
volume = {20},
number = {2},
pages = {206--217},
doi = {10.2215/cjn.0000000587}
}
EUVIMED